O. Reg. 13/10: Designated Drugs

 

ontario regulation 13/10

made under the

MIDWIFERY ACT, 1991

Made: October 29, 2009
Approved: January 20, 2010
Filed: January 22, 2010
Published on e-Laws: January 22, 2010
Printed in The Ontario Gazette: February 6, 2010

Amending O. Reg. 884/93

(Designated Drugs)

1. Section 1 of Ontario Regulation 884/93 is revoked and the following substituted:

1. For the purposes of paragraph 3 of section 4 of the Act, the following substances are designated as substances that a member may administer by injection on the member’s own responsibility:

Ampicillin — for the purpose of preventing neonatal group B streptococcal disease

Bupivacaine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Carbetocin

Carboprost tromethamine

Cefazolin — for the purpose of preventing neonatal group B streptococcal disease

Chloroprocaine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Clindamycin — for the purpose of preventing neonatal group B streptococcal disease

Dimenhydrinate

Diphenhydramine hydrochloride

Epinephrine hydrochloride

Ergonovine maleate

Erythromycin — for the purpose of preventing neonatal group B streptococcal disease

Hepatitis B immune globulin

Hepatitis B vaccine

Intravenous fluids

Lidocaine hydrochloride with or without epinephrine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Measles-mumps-rubella virus vaccine

Oxytocin

Penicillin G — for the purpose of preventing neonatal group B streptococcal disease

Phytonadione

RhD immune globulin

Varicella Zoster immune globulin

2. Section 3 of the Regulation is revoked and the following substituted:

3. For the purposes of paragraph 7 of section 4 of the Act, the following drugs are designated as drugs that a member may prescribe on the member’s own responsibility:

Amoxicillin-clavulanic acid — for the purpose of treating mastitis

Cephalexin — for the purpose of treating mastitis

Ciprofloxacin (oral)

Clotrimazole

Clindamycin (oral)

Cloxacillin (oral)

Diclofenac (oral)

Domperidone — for the purpose of promoting lactation

Doxylamine succinate-pyridoxine hydrochloride

Ergonovine maleate (oral)

Erythromycin ophthalmic ointment

Folic acid (oral; greater than 1mg/dose)

Hepatitis B immune globulin

Hepatitis B vaccine

Hydrocortisone anorectal therapy compound

Metronidazole (oral)

Miconazole

Misoprostol — for the purpose of preventing postpartum hemorrhage

Mupirocin-betamethasone valerate-miconazole (topical)

Naproxen (oral)

Nitrofurantoin — for the purpose of treating urinary tract infections

Nystatin

Phytonadione

RhD immune globulin

Sulfamethoxazole-trimethoprim (oral)

Trimethoprim — for the purpose of treating urinary tract infections

3. Section 4 of the Regulation is revoked and the following substituted:

4. (1) In the course of engaging in the practice of midwifery, a member may use any drug on the order of a member of the College of Physicians and Surgeons of Ontario.

(2) For the purposes of paragraph 3 of section 4 of the Act, a member may administer any substance by injection or inhalation on the order of a member of the College of Physicians and Surgeons of Ontario.

4. This Regulation comes into force on the day it is filed.

Made by:

Council of the College of Midwives of Ontario:

Andrea Lennox

President

Deborah Adams

Registrar & C.E.O.

Date made: October 29, 2009.